-
Remofuscin® prevented retinal thinning in Stargardt disease patients
Katairo GmbH, a biopharmaceutical company focused on discovering, developing and commercializing novel treatments for back of the eye diseases, today announced topline results of the STARTT study. The Stargardt Remofuscin Treatment Trial (STARTT) was a 2-year study comparing Remofuscin® tablets to placebo. The primary endpoint, quantitative autofluorescence (qAF), a novel method to quantify retinal autofluorescence, proved highly variable and did not show significant changes from baseline in both study groups. However, Remofuscin® treated patients had significantly less retinal thinning on tomographic images (SD-OCT) compared to placebo. This protective effect increased over time and was observed for both eyes. The beneficial outcome of Remofuscin® treatment was observed in several retinal structures,…